| The trend of monoclonal antibody (mAb)/antiviral use varied in relation to predominant SARS-CoV-2 variants. |
| The prevalence of use of mAbs/antiviral therapies for early treatment of COVID-19 outpatients increased slowly in England and in Italy. |
| Nirmatrelvir/ritonavir was the most frequently prescribed/administered antiviral in the most recent period. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.